WO2019088214A1 - 徐放性医薬組成物 - Google Patents
徐放性医薬組成物 Download PDFInfo
- Publication number
- WO2019088214A1 WO2019088214A1 PCT/JP2018/040634 JP2018040634W WO2019088214A1 WO 2019088214 A1 WO2019088214 A1 WO 2019088214A1 JP 2018040634 W JP2018040634 W JP 2018040634W WO 2019088214 A1 WO2019088214 A1 WO 2019088214A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- administration
- compound
- composition
- composition according
- salt
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present invention relates to a composition for topical administration comprising N- (2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclohexanecarboxamide or a salt thereof, and more particularly, to N- (2-ethylsulfonyl)
- the present invention relates to a composition for topical administration comprising amino-5-trifluoromethyl-3-pyridyl) cyclohexanecarboxamide or a salt thereof and a polycationic polymer.
- N- (2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclohexanecarboxamide or a salt thereof has a phospholipase A2 inhibitory action and is useful as an active ingredient of an anti-inflammatory agent or an anti-pancreatitis agent (Patent Document 1).
- Patent Documents 1 to 5 also describe preparations for oral administration, intravenous administration or subcutaneous administration, which comprise the above-mentioned active ingredients.
- the above-mentioned preparation can not maintain the effective concentration of the above-mentioned active ingredient, for example, in a living body for a long time, and may require multiple administrations to obtain a desired effect. Therefore, there is a need for development of a technical means capable of improving the sustained release ability so as to exert desired effects while reducing the frequency of administration.
- the present inventors have now reported that when N- (2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclohexanecarboxamide or a specific composition containing a salt thereof is administered to the body, It has been found that the sustained release ability of ethylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclohexanecarboxamide or a salt thereof is improved.
- the present invention relates to N- (2-ethylsulfonylamino-5-trifluoro) having an enhanced ability to release N- (2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclohexanecarboxamide or a salt thereof. It is an object of the present invention to provide a composition comprising methyl-3-pyridyl) cyclohexanecarboxamide or a salt thereof.
- the present invention includes the following inventions.
- composition according to (2) wherein the copolymer of acrylic acid ester and methacrylic acid ester having a positively charged nitrogen atom-containing group is ethyl acrylate, methyl methacrylate, trimethyl ammonium ethyl methacrylate copolymer .
- the polyamino acid is at least one selected from the group consisting of polylysine, polyarginine, polyhistidine, and polyornithine.
- the polycationic polymer is a biodegradable polymer.
- shape of the composition is particles.
- composition according to (6) wherein the particles are in a form suspended in a solvent.
- the hydrogel may be poly (alkylene oxide), poly (vinyl alcohol), alginic acid, hyaluronic acid, chondroitin sulfate, gelatin, dextran, polyethylene glycol, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, polyhydroxybuterate, poly
- composition according to (8) further comprising a hydrophilic polymer selected from the group consisting of (n-isopropyl acrylamide), carrageenan, pectin, dextran sulfate, and combinations thereof.
- Said local administration is subcutaneous administration, rectum administration, intraperitoneal administration, intraarticular administration, intraocular administration, intratumoral administration, perivascular administration, intracranial administration, intramuscular administration, periocular administration, intraocularlid administration
- Intraoral administration intranasal administration, intravesical administration, intravaginal administration, intraurethral administration, intrarectal administration, adventitial administration, or intranasal administration, according to any one of (1) to (9)
- Composition of (11) The composition according to any one of (1) to (10), which is a sustained release composition.
- (12) The composition according to any one of (1) to (11), for treating or preventing a disease, condition or symptom associated with inflammatory cells.
- composition according to any one of (1) to (12) for non-human animals comprising topically administering the composition according to any one of (1) to (13) to the non-human animal Treatment or prevention methods.
- the sustained release ability of N- (2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclohexanecarboxamide or a salt thereof can be effectively enhanced.
- Raw powder of N- (2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclohexanecarboxamide monosodium salt monohydrate (hereinafter also referred to as compound 1), composition containing compound 1 (microparticle A
- compound 1 composition containing compound 1
- microparticle A It is a graph which shows the result of evaluation evaluation of the elution property of compound 1 in -E).
- composition of the present invention is characterized in that it comprises a polycationic polymer together with N- (2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclohexanecarboxamide or a salt thereof.
- N- (2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclohexanecarboxamide or a salt thereof N- (2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclohexanecarboxamide in the present invention It is represented by the structural formula of Formula (1).
- N- (2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclohexanecarboxamide may be abbreviated as a compound of the formula (1).
- the salt of the compound of the formula (1) may be any pharmaceutically acceptable salt, for example, potassium salt, alkali metal salt such as sodium salt, alkaline earth metal salt such as calcium salt, triethanol And amine salts, organic amine salts such as tris (hydroxymethyl) aminomethane salts, and the like. Furthermore, the salt of the compound of the formula (1) may be one having crystal water among these salts, that is, a hydrate.
- the compound of the formula (1) or a salt thereof can be produced, for example, by the method described in JP-A 06-263735.
- the content of N- (2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclohexanecarboxamide or a salt thereof in the composition of the present invention is not particularly limited as long as the effects of the present invention are not impaired. It may be, for example, 0.01 to 50% by mass, preferably 0.05 to 30% by mass, more preferably 0.1 to 15% by mass or 0.1 to 20% by mass, based on the whole. .
- polycationic Polymers used in the present invention are not particularly limited, and include those used as pharmaceuticals or foods or those used in the future.
- the polycationic polymer of the present invention is not particularly limited as long as it is a positively charged polymer, as long as the effects of the present invention are exhibited.
- suitable polycationic polymers include polymers having positively charged nitrogen atom-containing groups such as amino groups, ammonium groups, imino groups and the like (positively charged nitrogen atom-containing polycationic polymers).
- the amino group primary, secondary and tertiary amino groups may be mentioned, and as the ammonium group, primary, secondary, tertiary and quaternary ammonium groups may be mentioned.
- the positively charged nitrogen atom-containing group includes not only a positively charged nitrogen atom-containing group but also a positively chargeable nitrogen atom-containing group.
- polycationic polymer examples include copolymers of acrylic acid ester and methacrylic acid ester having a positively chargeable nitrogen atom-containing group, polyamino acid, polyamine, polyamidoamine, polyimine, chitosan, poly N, N- Dimethylaminoethyl methacrylic acid, polyvinylpyridine, polyimidazole, polyvinylamine, polyvinylformamide, protamine, polythiodiethylaminomethylethylene, poly-p-aminostyrene, polycation carbohydrate, polycation polymethacrylate, polycation polyacrylate, polycation poly These include oxetanes, derivatives thereof and salts thereof, and combinations thereof, etc.
- acrylic acid esters having a positively chargeable nitrogen atom-containing group and methacrylic acid esters are preferable.
- an ethyl acrylate / methyl methacrylate / trimethyl ammonium methacrylate methacrylate copolymer is preferable.
- polyamino acids examples include polyamino acids having a positively charged nitrogen atom-containing group such as polylysine, polyarginine, polyhistidine, polyornithine and the like, with preference given to polylysine and polyarginine.
- polylysine examples include polylysine, ⁇ -polylysine and ⁇ -polylysine can be mentioned, and ⁇ -polylysine is preferable.
- polyamines include spermine, spermidine, putrescine and the like.
- the above salts preferably include pharmaceutically acceptable salts, more preferably sulfates and hydrochlorides.
- a biodegradable polymer may be used from the viewpoint of safety and biocompatibility.
- polycationic polymer For example, copolymers of acrylic acid ester and methacrylic acid ester such as trade name (the same as the following) Eudragit (registered trademark) (manufactured by Evonik); Eudragit (registered trademark) RS 100, PO, 30D, 12,5, etc. Eudragit Ethyl acrylate, methyl methacrylate, trimethyl ammonium ethyl methacrylate such as Eudragit (registered trademark) RL (manufactured by Evonik) such as (registered trademark) RS, Eudragit (registered trademark) RL 100, PO, 30D, 12, 5 etc. Copolymer etc. are mentioned.
- the above polymers may be used alone or, if necessary, in combination of two or more.
- Eudragit (registered trademark) RS and Eudragit (registered trademark) RL are used, the compounding ratio can control the release duration of the compound of formula (1) or a salt thereof.
- the blending ratio of Eudragit RS and Eudragit RL includes, for example, 100: 0 to 0: 100, and from the viewpoint of controlled release, 75:25 to 25:75 is preferable, and 75:25. ⁇ 50: 50 is more preferred.
- the weight average molecular weight of the polycationic polymer of the present invention may be, for example, 500 or more, preferably 500 to 200,000, and more preferably 2,000 to 50,000.
- the weight average molecular weight can be measured by size exclusion chromatography.
- the compound of the formula (1) or a salt thereof and a polycation polymer may form a complex (polyion complex), in which case an improvement in sustained release ability is expected.
- the polycationic polymer may be one which can form a polyion complex complex with the compound of the formula (1) or a salt thereof.
- the content of the polycationic polymer in the composition of the present invention is not particularly limited as long as the effects of the present invention are not impaired, and for example, 0.01 to 99% by mass can be mentioned with respect to the whole composition.
- the content can be made 05 to 95% by mass, more preferably 0.1 to 90% by mass.
- the mass ratio of the compound of the formula (1) or a salt thereof to the polycationic polymer does not interfere with the effects of the present invention
- the composition of the present invention when the composition of the present invention is in the form of a hydrogel, the composition may comprise a hydrophilic polymer.
- the hydrophilic polymer to be used is not particularly limited, and includes those used as a pharmaceutical or food or used in the future.
- the hydrophilic polymer used in the hydrogel is a high molecular weight substance (water-swellable polymer) which swells and becomes gel when contacted with water, or has a high molecular weight which becomes gel at a specific temperature.
- a substance heat sensitive polymer
- hydrophilic polymer examples include poly (alkylene oxide), poly (vinyl alcohol), alginic acid, hyaluronic acid, chondroitin sulfate, gelatin, dextran, polyethylene glycol, hydroxymethyl cellulose, polyhydroxybuterate, poly (n-isopropyl) Acrylamide), carrageenan, pectin, dextran sulfate, poly (acrylic acid), hydroxypropyl methylcellulose, hydroxypropyl cellulose, methyl cellulose, sodium carboxymethyl cellulose, hydroxyethyl cellulose, polyvinyl pyrrolidone, carboxyvinyl polymer, and combinations thereof.
- hydrophilic polymer in order to form a gel at a specific temperature, a polymer compound having a cloud point may be used, and these polymer compounds have, for example, hydrophilicity such as amide group and carbonyl group in the molecule Preparing by polymerizing a monomer having both a group and a hydrophobic group such as a linear or branched alkyl group or a cycloalkyl group, or introducing a hydrophilic group and a hydrophobic group into a polymer compound Can.
- the above-mentioned hydrophilic polymers may be used alone or in combination of two or more if necessary.
- Preferred hydrophilic polymers are poly (alkylene oxide), hyaluronic acid, pectin, and a more preferred hydrophilic polymer is poly (ethylene oxide).
- These hydrophilic polymers may be commercially available ones.
- trade name (same below) Poly (ethylene oxide) [weight average molecular weight: 8 million, viscosity: 10000-15000 mPa ⁇ s (1% aqueous solution 25 ° C.)] (Sigma Aldrich), Polyox WSR Coagulant [weight average molecular weight: 5 million, viscosity: 5500-7500 mPa ⁇ s (1% aqueous solution 25 ° C.)] (made by DOW), Polyox WSR-301 [average molecular weight: 4 million, viscosity: 1650-5500 mPa ⁇ s (1% aqueous solution 25 ° C.)] (DOW company), Polyox WSR-N-60K [weight average molecular weight: 2,000,000, vis
- the weight average molecular weight of the hydrophilic polymer is, for example, 100,000 or more, preferably 100,000 to 10,000,000, and more preferably 500,000 to 9,000,000.
- the viscosity of the hydrophilic polymer is, for example, 1 mPa ⁇ s or more as a 1% aqueous solution at 25 ° C., preferably 1000 Pa ⁇ s, more preferably 2000 to 50000 mPa ⁇ s, further preferably 5000 to 30000 mPa ⁇ s. s.
- the release period of the compound of formula (1) or a salt thereof from the composition can be optionally controlled by adjusting the viscosity or weight average molecular weight of the hydrophilic polymer.
- the polycationic polymer used in the hydrogel is a copolymer of acrylic acid ester and methacrylic acid ester having a positively chargeable nitrogen atom-containing group, polyamino acid, polyamine, protamine, etc.
- the hydrophilic polymer selected from the group consisting of derivatives of these and salts thereof and combinations thereof and used in hydrogels is selected from the group consisting of poly (alkylene oxide), hyaluronic acid, pectin and combinations thereof.
- the polycationic polymer used in the hydrogel is a polyamine and the hydrophilic polymer used in the hydrogel is a poly (alkylene oxide).
- composition of the present invention optionally contains a pharmaceutically or orally acceptable additive.
- additives are not particularly limited, but include aqueous media such as purified water, solvents, bases, solubilizers, tonicity agents, stabilizers, preservatives, preservatives, surfactants, modifiers, chelates.
- Agents, pH adjusters, buffers, excipients, thickeners, colorants, fragrances, flavors, antioxidants, dispersants, disintegrants, plasticizers, emulsifiers, solubilizers, reducing agents, sweeteners, A flavoring agent, a binder, etc. are mentioned and it can mix
- examples of the base include glycerin tri (caprylic acid / capric acid), a polylactic acid glycolic acid copolymer (hereinafter also referred to as PLGA).
- a commercial item can be used as tri (caprylic acid * capric acid) glycerol,
- Coconad MT made by Kao Corp.
- PLGA can use a commercial item, for example, RESOMER RG503 (made by Sigma Aldrich) is mentioned.
- the surfactant nonionic, anionic, cationic or amphoteric surfactants usually used in the technical field can be appropriately selected and used. For example, sorbitan monooleate, polyricinolein Acid polyglyceryl and the like.
- Sorbitan monooleate can use a commercial item, for example, span 80 (made by Croda international PLC) is mentioned.
- polyglyceryl polyricinoleate can also be a commercially available product, and examples thereof include NIKKOL Hexaglyn PR-15 (polyglyceryl-6 polyricinolenic acid) (manufactured by Nippon Surfactant Industries Co., Ltd.).
- the composition of the present invention may be in any form as long as the effects of the present invention are not impaired.
- the composition include liquid (including oil and slurry), semi-solid (including paste and gel), and solid, and preferred are particles and hydrogels.
- the particles may be in the form of being suspended in a solvent, and examples of the solvent include water, physiological saline, vegetable oil and propylene glycol.
- the hydrogel of the present invention may be liquid (including oil and slurry) or gel at the time of administration, but it may be liquid or solid (powder) at the time of administration. It may be in situ in situ into a hydrogel, and the hydrogel of the present invention includes such an embodiment.
- the composition comprising the compound of the formula (1) of the present invention or a salt thereof comprises a combination of the compound of the formula (1) or a salt thereof and a polycationic polymer, as long as the characteristics of the combination are retained.
- the dosage form is not particularly limited, and injections, suppositories, ointments, creams, gels, patches, drops, eye drops, nasal drops, eye ointments, poultices, liniments, lotions, creams It can be provided as an agent, suspension, emulsion, syrup, oral jelly, embedded injection, sustained injection, semisolid preparation for rectum, enema and the like.
- the above dosage form is preferably a dosage form for topical administration, and includes injections, suppositories and the like.
- the injection includes a form of a kit comprising the composition of the present invention and a solvent for suspending the composition, and the solvent includes water, physiological saline, vegetable oil and propylene glycol. .
- the above composition can be topically administered to efficiently deliver the compound of formula (1) or a salt thereof to the body.
- the topical administration of the present invention refers to a dosage form in which the compound of the formula (1) or a salt thereof is retained locally (at the administration site) and absorbed in the body.
- the composition for topical administration of the present invention can be suitably used not only for local action but also for systemic action.
- intramuscular administration for example, intramuscular administration, subcutaneous administration, intradermal administration, transmucosal administration such as transrectal administration, transdermal administration, intranasal administration, intraoral administration, intraperitoneal administration, intraarticular administration, intraocular administration
- intraocular administration Intratumoral administration, perivascular administration, intracranial administration, periocular administration, intraocular lidar administration, intravesical administration, intravaginal administration, intraurethral administration, intrarectal administration, adventitial administration, parenteral administration such as nasal administration, etc.
- the composition of the present invention is provided as a composition for subcutaneous administration.
- composition of the present invention can significantly improve the sustained release ability of the compound of the formula (1) or a salt thereof as shown in the following examples.
- the composition of the present invention is provided as a sustained release composition of the compound of formula (1) or a salt thereof.
- the composition of the present invention can be produced by mixing the compound of the formula (1) or a salt thereof and a polycationic polymer.
- the mixing method is not particularly limited as long as the composition of the present invention is obtained and the method of the present invention is not disturbed.
- kneading by heat melting method precipitation method such as emulsion solvent diffusion method Bottom-up method, mechanochemical method and the like.
- An example is to prepare a mixture comprising a compound of formula (1) or a salt thereof, a polycationic polymer and optionally a solvent.
- the above production method may further include drying or cooling the mixture.
- the drying is not particularly limited as long as the solvent can be sufficiently dried, and examples thereof include spray drying, lyophilization, and a combination thereof. Drying efficiency, powder recovery rate and economy, production scale up Spray drying is preferred from the viewpoint of
- the solvent used for the preparation of the above mixture is not particularly limited, and includes one used as a pharmaceutical or food or used in the future.
- the above solvents include water, aliphatic halogenated hydrocarbons (eg, dichloromethane, dichloroethane, chloroform etc.), alcohols (eg, methanol, ethanol, propanol etc.), ketones (eg acetone, methyl ethyl ketone) Etc.), ethers (eg, diethyl ether, dibutyl ether, 1,4-dioxane etc.), aliphatic hydrocarbons (eg, n-hexane, cyclohexane, n-heptane etc.), aromatic hydrocarbons (eg, Benzene, toluene, xylene etc., organic acids (eg, acetic acid, propionic acid etc.), esters (eg, ethyl acetate etc.), amides (e
- the mixture is a good solvent solution in which the compound of the formula (1) or a salt thereof and a polycationic polymer are dissolved, and the good solvent solution and the poor solvent are mixed. It may further include. That is, the method of producing the composition of the present invention may be an emulsion solvent diffusion method. An example of a specific manufacturing method is shown below. First, the compound of formula (1) or a salt thereof is mixed with a good solvent, and the obtained mixture (mixture) is mixed with a polycationic polymer solution, and the compound of formula (1) or a salt thereof and a polycationic polymer The dissolved good solvent solution is obtained.
- the good solvent solution is mixed with the poor solvent dropwise or the like to obtain a suspension comprising the compound of the formula (1) or a salt thereof and the polycationic polymer.
- the suspension is then washed, frozen and then dried to obtain a composition comprising a compound of formula (1) or a salt thereof and a polycationic polymer.
- the composition obtained is preferably particles, and more preferably fine particles such as nanoparticles.
- the good solvent is not particularly limited as long as it can dissolve the compound of the formula (1) or a salt thereof, and examples thereof include water, ethanol and isopropyl alcohol, preferably water and ethanol.
- the solvent used for the polycationic polymer solution is not particularly limited as long as it can dissolve the polycationic polymer, and examples thereof include acetone, butanol, ethyl acetate and dioxane, and preferably acetone and butanol.
- the polycationic polymer solution may contain a surfactant. Therefore, a good solvent solution in which the compound of the formula (1) or a salt thereof and the polycationic polymer are dissolved may contain the solvent in the polycationic polymer solution together with the good solvent.
- the poor solvent is not particularly limited as long as it is a solvent which hardly dissolves the compound of the formula (1) or a salt thereof, and examples thereof include hexane, diethyl ether, chloroform and tetrahydroxyfuran. It is ether.
- the poor solvent may contain a surfactant and a base.
- the composition when the composition is a hydrogel, for example, a mixture comprising the compound of the formula (1) or a salt thereof, a polycationic polymer, a hydrophilic polymer and optionally a solvent It can be prepared.
- solvents include the same solvents as those used for the preparation of the above mixture, preferably water, ethanol, acetone and ethyl acetate.
- the obtained hydrogel may be further dried to be solid. The drying is not limited in any way as long as the solvent can be sufficiently dried, and examples thereof include spray drying, lyophilization and combinations thereof.
- composition for topical administration comprising the compound of the formula (1) of the present invention or a salt thereof comprises inflammatory cells (eg, granulocytes (neutrophils, eosinophils, basophils), lymphocytes (eg, Diseases, conditions or symptoms associated with T lymphocytes, NK cells), monocytes, macrophages, plasma cells, mast cells, platelets (eg, pancreatitis, surgical invasion, disseminated intravascular coagulation (DIC), neoplastic Disease, uterine empyema, heat stroke, immune-mediated hemolytic anemia (IMHA), sepsis, angiosarcoma, gastric torsion, ischemia reperfusion injury, purpura, liver failure, hepatitis, pneumonia, systemic inflammatory response syndrome (SIRS), Trauma, osteoarthritis, cystitis, disc disease, atopy / allergy, dermatitis, immune-mediated disease, otitis, inflammatory bowel disease, chronic pain, colitis, chronic o
- the composition for topical administration of the present invention can exert therapeutic and preventive action on pancreatitis, surgical invasion, disseminated intravascular coagulation syndrome (DIC) and the like.
- the composition of the present invention is a disease, condition or condition associated with inflammatory cells, preferably pancreatitis, surgical invasion or disseminated intravascular coagulation (DIC)
- DIC disseminated intravascular coagulation
- the composition of the present invention can also be used as a pharmaceutical or quasi drug for humans or animals.
- the composition of the present invention may be appropriately used in combination with other pharmaceuticals and quasi-drugs commonly used in the technical field, as needed.
- the subject to which the composition of the present invention is applied includes, for example, animals, preferably non-human animals such as mammals, birds, reptiles, amphibians and fish, more preferably mice. , Rats, rabbits, dogs, cats, pigs, cows and horses.
- the animal may be a domestic animal, a pet, a breeding animal, a wild animal, or a competition animal.
- the subject may be a healthy person (healthy animal) or a patient (patient animal).
- an inflammatory cell of a subject comprising topically administering to the subject a composition of the present invention comprising an effective amount of the compound of formula (1) or a salt thereof.
- the method for preventing a disease, condition or symptom associated with inflammatory cells in a subject as described above is a non-therapeutic method excluding medical practice when the subject is a healthy person and Be done. Methods of treating or preventing inflammatory cell-related diseases, conditions, symptoms and the like of the subject of the present invention can be practiced according to the contents described herein for the composition of the present invention.
- topical administration of a composition of the present invention comprising an effective amount of a compound of formula (1) or a salt thereof to a subject
- a composition of the present invention comprising an effective amount of a compound of formula (1) or a salt thereof to a subject
- methods for improving the sustained release ability of a compound or a salt thereof are provided.
- the effective amount of the compound of the formula (1) of the present invention or a salt thereof and the number of times of administration of the composition of the present invention are not particularly limited. Depending on the dosage form, duration of drug release, type of subject, nature, sex, age, symptoms and the like, it is appropriately determined by those skilled in the art.
- the effective amount of the compound of formula (1) or a salt thereof is 0.01 to 1000 mg / kg body weight, preferably 0.05 to 500 mg / kg body weight.
- the frequency of administration may be, for example, once a day to once a few days, once a few weeks, once a month, etc.
- the duration of release of the compound of formula (1) or a salt thereof from the composition of the present invention varies depending on the type of the compound of formula (1) or a salt thereof, the dosage form of the composition, the dose or the administration site
- the lower limit is, for example, 3 hours or more, preferably 6 hours or more, more preferably 12 hours or more
- the upper limit is, for example, 1 year or less, preferably 4 months or less, more preferably 2 months or less is there.
- the use of a combination of a compound of formula (1) or a salt thereof and a polycationic polymer in the manufacture of a composition for topical administration is provided.
- the composition is a disease, condition, or condition associated with inflammatory cells, preferably, pancreatitis, surgical invasion, or disseminated intravascular coagulation (DIC). It is used for treatment or prevention.
- a combination of a compound of formula (1) or a salt thereof and a polycationic polymer for topical administration.
- a disease, condition or condition associated with inflammatory cells preferably pancreatitis, surgical invasion or disseminated intravascular coagulation (DIC)
- DIC disseminated intravascular coagulation
- a combination of a compound of formula (1) or a salt thereof and a polycationic polymer for topical administration preferably pancreatitis, surgical invasion or disseminated intravascular coagulation (DIC)
- DIC disseminated intravascular coagulation
- PLGA RESOMER RG 503
- Sigma Aldrich polyvinyl alcohol weight average molecular weight: 31,000-50,000
- Sigma Aldrich protamine sulfate Wako Pure Chemical Industries, Ltd.
- the apparatus used by the test example and the reference example is as follows. Vortex mixer; IKA Homogenizer: Microtech Co., Ltd. Cooling centrifuge: Hitachi Koki Co., Ltd. Deep freezer: Japan Freezer Co., Ltd. Freeze dryer: FD-1000, Tokyo Rika Co., Ltd. shaker: INCUBATOR M- 100, TAITEC Co., Ltd. ultra-high performance liquid chromatography: Aquity UPLC, Waters Co., Ltd. fine particle preparation apparatus: spray dryer ADL 311 S, Yamato Scientific Co., Ltd.
- Reference Example 1 Examination of Compound 1-containing Composition (Particles a) Reference Example 1-1 Preparation of Compound 1-Containing Composition (Particles a) Compound 1 (8 mg) and purified water (0.8 mL) were mixed by a vortex mixer to obtain a liquid a. PLGA (40 mg), span 80 (40 mg), and acetone (1.2 mL) were mixed by a vortex mixer to obtain liquid b. Liquid a and liquid b were mixed by a vortex mixer to obtain liquid c. NIKKOL Hexaglyn PR-15 (240 mg), Coconard MT (12 mL), and hexane (8 mL) were mixed by a vortex mixer to obtain a liquid d.
- Polyvinyl alcohol (100 mg) and purified water (10 mL) were stirred by a magnetic stirrer to give a liquid e.
- the liquid c was dropped to the liquid d, and stirred for 5 minutes at 15,000 rpm using a homogenizer to obtain a suspension.
- the resulting suspension was centrifuged at 20,000 rpm for 10 minutes at 4 ° C. in a refrigerated centrifuge, and the supernatant was discarded to obtain a precipitate.
- Hexane (10 mL) is added to the obtained precipitate and stirred for 5 minutes with a vortex mixer to give a suspension, and centrifuged at 20,000 rpm for 10 minutes at 4 ° C.
- Reference Example 1-2 Elution Characteristics of Compound 1-Containing Composition (Particles a)
- An evaluation test of the dissolution of the microparticles a prepared in Reference Example 1-1 was conducted in the same manner as in Test Example 1 described later. Specifically, fine particles a (10 mg) were added to phosphate buffered saline (pH 7.4, 30 mL), shaking was performed at 37 ° C. for 24 hours, shaking speed 60 strokes / min, shaking width 2 using a shaker. Shake horizontally at .0 cm / stroke and evaluate "elution”. The concentration of Compound 1 was quantified using ultra high performance liquid chromatography with a single quadrupole mass spectrometer as a detector to calculate the elution rate. The test results of the fine particles a are shown in Table 1 below together with the test results of the bulk powder of Compound 1 obtained in Test Example 1 described later.
- NIKKOL Hexaglyn PR-15 (240 mg), Coconard MT (12 mL), and hexane (8 mL) were mixed by a vortex mixer to obtain Liquid D.
- the liquid C was dropped to the liquid D and stirred for 5 minutes at 15,000 rpm using a homogenizer to obtain a suspension.
- the resulting suspension was centrifuged at 20,000 rpm for 10 minutes at 4 ° C. in a refrigerated centrifuge, and the supernatant was discarded to obtain a precipitate.
- Hexane (10 mL) is added to the obtained precipitate and stirred for 5 minutes with a vortex mixer to give a suspension, and centrifuged at 20,000 rpm for 10 minutes at 4 ° C.
- Test Example 1-2 Elution Characteristics of the Compound 1-Containing Composition (Particles A to E)
- the fine particles A, B, C, D, E, and Compound 1 raw powder prepared in Test Example 1-1 were used to The dissolution evaluation test was conducted.
- Microparticles A, B, C, D, E, and raw powder of compound 1 (10 mg) were added to phosphate buffered saline (pH 7.4, 30 mL), respectively, using a shaker for 24 hours at 37 ° C.
- the sample was horizontally shaken at a shaking speed of 60 strokes / minute and a shaking width of 2.0 cm / stroke to evaluate "elution".
- the concentration of Compound 1 was quantified using ultra high performance liquid chromatography with a single quadrupole mass spectrometer as a detector to calculate the elution rate. The results are shown in Table 2 below and FIG.
- each particle of Test Example 1 showed the characteristics of the controlled release particle. It was possible to control the release rate of Compound 1 by encapsulating a water-soluble compound such as Compound 1 in the polycationic polymer by the emulsion solvent diffusion method. In addition, it was possible to control the release rate by changing the composition of Eudragit RS and Eudragit RL. This is presumably because Compound 1 is uniformly dispersed in Eudragit RS and Eudragit RL in the prepared microparticles F, and when water intrudes into the particles, the compound 1 is gradually released from the surface of the microparticles.
- Test Example 1-3 Pharmacokinetic Evaluation of Compound 1-Containing Composition (Microparticles B)
- the blood concentration of Compound 1 was measured over time.
- the microparticles B were suspended in physiological saline, and the bulk powder of Compound 1 was dissolved in physiological saline, and then 5 mg / kg of Compound 1 was administered in a single dose to male SD rats. After administration, blood was collected from the tail vein over time, transferred to a heparinized microtest tube, and immediately ice-cooled.
- the blood was immediately centrifuged at 10,000 g for 10 minutes at 4 ° C.
- the concentration of compound 1 in the obtained plasma was quantified by ultra-performance liquid chromatography using a single quadrupole mass spectrometer as a detector.
- C max , T max , T 1/2 , AUC 0- ⁇ and BA are respectively the highest blood concentration (the concentration at the peak of the blood concentration curve) and the time to reach the highest blood concentration (blood concentration) The time to reach the peak of the curve), the half-life of the blood concentration of the drug, the area under the blood concentration curve (Area under curve) from the start of administration to the drug disappearance, and the bioavailability (Bioavailability) .
- microparticles B prepared in Test Example 1 had a reduced rate of absorption and elimination of Compound 1 compared to the bulk powder of Compound 1 administered subcutaneously.
- microparticles B showed approximately twice as high BA as compared with the bulk powder of Compound 1 orally administered at the same dose.
- the C max of microparticles B decreased 41.7% as compared with the bulk of Compound 1 administered subcutaneously.
- T 1/2 of fine particle B is extended by 0.76 hours as compared with T 1/2 of the bulk powder of compound 1 subcutaneously administered, and fine particle B of test example 1 has a retention property in blood of compound 1 It showed an increase. It is presumed that this is due to the particles B prepared in Test Example 1 having sustained release drug elution characteristics.
- the conditions are as follows. -Particle preparation conditions- Inlet temperature: 130 ° C Outlet temperature: 77 ° C. or more and 82 ° C. or less Average circulation air volume: 0.47 m 3 / min Air pressure: 0.1MPa Nozzle diameter: 0.4 mm Liquid transfer speed: 3.01 g / min Trap temperature: -2 ° C
- Test Example 2-2 Elution Characteristics of Compound 1-Containing Composition (Particles F) Using the fine particles F prepared in Example 2-1 and the bulk powder of Compound 1, evaluation of the respective elution properties is carried out similarly to Test Example 1. The test was done. Microparticles F, bulk powder of Compound 1 (10 mg) are added to phosphate buffered saline (pH 7.4, 30 mL), respectively, using a shaker for 72 hours at 37 ° C., shaking speed 60 strokes / min, shaking width Horizontal shaking was performed at 2.0 cm / stroke to evaluate "elution”. The results are shown in Table 4 below and FIG.
- microparticles F of Test Example 2 exhibited the characteristics of controlled release particles. It was possible to control the release rate of Compound 1 by encapsulating a water-soluble compound such as Compound 1 in a polycationic polymer by a spray drying method. This is presumably because Compound 1 is uniformly dispersed in Eudragit RS and Eudragit RL in the prepared microparticles F, and when water intrudes into the particles, the compound 1 is gradually released from the surface of the microparticles. .
- Test Example 2-3 Pharmacokinetic Evaluation of Compound 1-Containing Composition (Microparticles F)
- microparticles F or compound 1 bulk powder prepared in Test example 2-1 was used as a rat.
- the blood concentration of Compound 1 was measured over time.
- the method was the same as in Test Example 1-3. Specifically, microparticles F were suspended in saline, and the bulk powder of Compound 1 was dissolved in saline, and then 5 mg / kg of Compound 1 was administered subcutaneously to SD male rats, respectively. .
- blood was collected from the tail vein over time, transferred to a heparinized microtest tube, and immediately ice-cooled.
- the fine particles F prepared in Test Example 2 had a reduced absorption and disappearance rate of Compound 1 compared to the bulk powder of Compound 1.
- the C max of the fine particles F showed a 27-fold lower value than that of the raw powder of Compound 1.
- the T 1/2 of the microparticles F was extended for 5.19 hours as compared with the bulk compound 1 powder, and the microparticles F of Test Example 2 showed an increase in the retention of the compound 1 in blood.
- the plasma concentration of the bulk powder of Compound 1 was below the detection limit, while the plasma concentration of microparticles F was 43 ng / mL. This is presumed to be due to the fact that the microparticles F prepared in Test Example 2 have sustained release drug elution characteristics.
- Reference Example 3 Examination of Compound 1-containing Composition (Hydrogel a) Reference Example 3-1 Preparation of Compound 1 -Containing Composition (Hydrogel a) Compound 1 (1.5 mg), polyethylene oxide (13.5 mg), and purified water (0.9 mL) were mixed by a vortex mixer, and 4 It was stored overnight at ° C to obtain hydrogel a.
- the concentration of Compound 1 in the obtained plasma was quantified by ultra high performance liquid chromatography using a single quadrupole mass spectrometer as a detector. The results are shown in FIG. Table 6 below shows pharmacokinetic parameters calculated from the results of drug blood concentration measurement.
- the hydrogel a prepared in Reference Example 3 had a reduced absorption and disappearance rate of Compound 1 compared to the bulk powder of Compound 1.
- the C max of hydrogel a was reduced by 34.5% as compared with the bulk powder of Compound 1.
- T 1/2 of hydrogel a was extended by 0.19 hours as compared with the bulk of compound 1 powder, and hydrogel a of Reference Example 3 showed an increase in the retention of compound 1 in blood. It is presumed that this is due to the hydrogel a prepared in Reference Example 3 having sustained release drug elution characteristics. It was confirmed that Hydrogel a had sustained release, but it was considered that there is room for improvement in practical use.
- Test Example 5 Study of Compound 1-Containing Composition (Hydrogel A) Test Example 5-1 Preparation of Compound 1-Containing Composition (Hydrogel A) Compound 1 (1.5 mg), polyethylene oxide (13.5 mg), ⁇ -polylysine (1.5 mg), and purified water (0.9 mL) ) was mixed by a vortex mixer and stored overnight at 4 ° C. to obtain hydrogel A.
- Test Example 5-2 Pharmacokinetic Evaluation of Compound 1-Containing Composition (Hydrogel A)
- the hydrogel A or Compound 1 powder powder After subcutaneous administration to rats, the blood concentration of Compound 1 was measured over time. Specifically, 5 mg / kg of the active ingredient of hydrogel A or compound 1 as the amount of compound 1 was administered subcutaneously to a single SD male rat. After subcutaneous administration, blood was collected sequentially from the tail vein over time, transferred to a heparinized microtest tube, and immediately ice-cooled. After ice cooling, the blood was immediately centrifuged at 10,000 g for 10 minutes at 4 ° C.
- the concentration of Compound 1 in the obtained plasma was quantified by ultra high performance liquid chromatography using a single quadrupole mass spectrometer as a detector. The results are shown in FIG. Table 7 below shows pharmacokinetic parameters calculated from the results of blood concentration measurement of Compound 1.
- the hydrogel A prepared in Test Example 5 had a reduced absorption and disappearance rate of Compound 1 compared to the bulk powder of Compound 1.
- the Cmax of hydrogel A was reduced by 56% as compared with the bulk powder of Compound 1.
- T 1/2 of hydrogel A was extended by 0.48 hours as compared with the bulk powder of compound 1, and hydrogel A of test example 5 showed an increase in retention of blood of compound 1 in blood.
- the plasma concentration of Compound 1 in the bulk powder of Compound 1 was below the detection limit, while the plasma concentration of Compound 1 in Hydrogel A was 5 ng / mL. It is presumed that this is due to the hydrogel A prepared in Test Example 5 having sustained release drug elution characteristics.
- T max and T 1/2 of the hydrogel A of Test Example 5 were longer than T max and T 1/2 of the hydrogel a of Reference Example 3, respectively.
Abstract
Description
(1) N-(2-エチルスルホニルアミノ-5-トリフルオロメチル-3-ピリジル)シクロヘキサンカルボキサミドまたはその塩と、
ポリカチオンポリマーと
を含んでなる、局所投与用組成物。
(2) 前記ポリカチオンポリマーが、陽荷電性窒素原子含有基を有するアクリル酸エステルとメタクリル酸エステルのコポリマー、ポリアミノ酸、ポリアミン、ポリアミドアミン、ポリイミン、キトサン、ポリN,N-ジメチルアミノエチルメタクリル酸、ポリビニルピリジン、ポリイミダゾール、ポリビニルアミン、ポリビニルホルムアミド、プロタミン、ポリチオジエチルアミノメチルエチレン、ポリ-p-アミノスチレン、ポリカチオン炭水化物、ポリカチオンポリメタクリレート、ポリカチオンポリアクリレート、ポリカチオンポリオキセタン、これらの誘導体およびこれらの塩ならびにこれらの組合せからなる群から選択される、(1)に記載の組成物。
(3) 陽荷電性窒素原子含有基を有するアクリル酸エステルとメタクリル酸エステルのコポリマーが、アクリル酸エチル・メタアクリル酸メチル・メタアクリル酸トリメチルアンモニウムエチルコポリマーである、(2)に記載の組成物。
(4) ポリアミノ酸が、ポリリジン、ポリアルギニン、ポリヒスチジン、およびポリオルニチンからなる群から選択される少なくとも1種である、(2)に記載の組成物。
(5) 前記ポリカチオンポリマーが生分解性ポリマーである、(1)~(4)のいずれか一つに記載の組成物。
(6) 前記組成物の形状が粒子である、(1)~(5)のいずれか一つに記載の組成物。
(7) 前記粒子が、溶媒に懸濁した形態である、(6)に記載の組成物。
(8) 前記組成物の形状がハイドロゲルである、(1)~(5)のいずれか一つに記載の組成物。
(9) 前記ハイドロゲルが、ポリ(アルキレンオキサイド)、ポリ(ビニルアルコール)、アルギン酸、ヒアルロン酸、コンドロイチン硫酸、ゼラチン、デキストラン、ポリエチレングリコール、メチルセルロース、ヒドロキシメチルセルロース、ヒドロキシエチルセルロース、ポリヒドロキシブテレート、ポリ(n-イソプロピルアクリルアミド)、カラギーナン、ペクチン、硫酸デキストラン、およびそれらの組合せからなる群から選択される親水性ポリマーをさらに含んでなる、(8)に記載の組成物。
(10) 前記局所投与が、皮下投与、経直腸投与、腹腔内投与、関節内投与、眼内投与、腫瘍内投与、血管周囲投与、頭蓋内投与、筋肉内投与、眼周囲投与、眼瞼内投与、口腔内投与、鼻腔内投与、膀胱内投与、膣内投与、尿道内投与、直腸内投与、外膜投与、または経鼻投与である、(1)~(9)のいずれか一つに記載の組成物。
(11) 徐放性組成物である、(1)~(10)のいずれか一つに記載の組成物。
(12) 炎症性細胞が関連する疾患、病態、または症状の治療または予防のための、(1)~(11)のいずれか一つに記載の組成物。
(13) 非ヒト動物のための、(1)~(12)のいずれか一つに記載の組成物。
(14) (1)~(13)のいずれか一つに記載の組成物を非ヒト動物に局所投与することを含んでなる、非ヒト動物の炎症性細胞が関連する疾患、病態、または症状の治療または予防方法。
(15) (1)~(14)のいずれか一つに記載の組成物の製造方法であって、
N-(2-エチルスルホニルアミノ-5-トリフルオロメチル-3-ピリジル)シクロヘキサンカルボキサミドまたはその塩とポリカチオンポリマーとを含む混合物を調製すること
を含んでなる、方法。
(16) 前記混合物を乾燥させることをさらに含んでなる、(15)に記載の製造方法。
(17) 前記乾燥が、噴霧乾燥、凍結乾燥、およびそれらの組合せからなる群から選択される、(16)に記載の製造方法。
(18) 前記混合物がN-(2-エチルスルホニルアミノ-5-トリフルオロメチル-3-ピリジル)シクロヘキサンカルボキサミドまたはその塩とポリカチオンポリマーとを溶解させた良溶媒溶液であり、
該良溶媒溶液と貧溶媒とを混合すること
を含んでなる、(15)に記載の製造方法。
本発明におけるN-(2-エチルスルホニルアミノ-5-トリフルオロメチル-3-ピリジル)シクロヘキサンカルボキサミドは下記式(1)の構造式で表される。以下、N-(2-エチルスルホニルアミノ-5-トリフルオロメチル-3-ピリジル)シクロヘキサンカルボキサミドを式(1)の化合物と略記することもある。
式(1)の化合物またはその塩は、例えば、特開平06-263735号公報に記載の方法により製造することができる。
本発明において使用されるポリカチオンポリマーとしては、特に限定されるものではなく、医薬品あるいは食品として使用され、または将来使用されるものが含まれる。
本発明の組成物の形状がハイドロゲルである場合には、該組成物は親水性ポリマーを含んでもよい。使用される親水性ポリマーとしては、特に限定されるものではなく、医薬品あるいは食品として使用され、または将来使用されるものが含まれる。
上記親水性ポリマーは、各々単独で用いても良いが、必要により任意の2種以上の組み合わせで用いてもよい。好ましい親水性ポリマーは、ポリ(アルキレンオキサイド)、ヒアルロン酸、ペクチンであり、より好ましい親水性ポリマーは、ポリ(エチレンオキサイド)である。
これら親水性ポリマーは、市販のものを使用しても良い。例えば、商品名(以下同様)Poly(ethyleneoxide)[重量平均分子量:800万、粘度:10000-15000mPa・s(1%水溶液25℃)](Sigma Aldrich社製)、Polyox WSR Coagulant[重量平均分子量:500万、粘度:5500-7500mPa・s(1%水溶液25℃)](DOW社製)、Polyox WSR-301[平均分子量:400万、粘度:1650-5500mPa・s(1%水溶液25℃)](DOW社製)、Polyox WSR-N-60K[重量平均分子量:200万、粘度:2000-4000mPa・s(2%水溶液25℃)](DOW社製)、Polyox WSR-N-12K[重量平均分子量:100万、粘度:400-800mPa・s(2%水溶液25℃)](DOW社製)、Polyox WSR-1105[重量平均分子量:90万、粘度:8800-17600mPa・s(5%水溶液25℃)](DOW社製)、Polyox WSR-205[重量平均分子量:60万、粘度:4500-8800mPa・s(5%水溶液25℃)](DOW社製)、Polyox WSR-N-750[重量平均分子量:30万、粘度:600-1200mPa・s(5%水溶液25℃)](DOW社製)、Polyox WSR-N-80[重量平均分子量:20万、粘度:55-90mPa・s(5%水溶液25℃)](DOW社製)、Polyox WSR-N-10[重量平均分子量:10万、粘度:12-50mPa・s(5%水溶液25℃)](DOW社製)のポリ(エチレンオキサイド)等が挙げられる。
本発明のハイドロゲルにおいては、親水性ポリマーの粘度または重量平均分子量を調節することによって、該組成物からの式(1)の化合物またはその塩の放出期間を任意にコントロールすることができる。
ここで、本発明の局所投与とは、式(1)の化合物またはその塩を局所(投与部位)に滞留させて体内に吸収させる投与形態をいう。本発明の局所投与用組成物は、局所作用のみならず全身作用のために好適に用いることができる。
かかる局所投与としては、例えば、筋肉内投与、皮下投与、皮内投与、経直腸等の経粘膜投与、経皮投与、鼻腔内投与、口腔内投与、腹腔内投与、関節内投与、眼内投与、腫瘍内投与、血管周囲投与、頭蓋内投与、眼周囲投与、眼瞼内投与、膀胱内投与、膣内投与、尿道内投与、直腸内投与、外膜投与、経鼻投与等の非経口投与等が挙げられる。本発明の好ましい態様によれば、本発明の組成物は皮下投与用の組成物として提供される。
具体的な製造方法の一例を以下に示す。まず、式(1)の化合物またはその塩を良溶媒と混合し、得られた混合物(混合液)をポリカチオンポリマー溶液と混合し、式(1)の化合物またはその塩とポリカチオンポリマーとを溶解させた良溶媒溶液を得る。その後、上記良溶媒溶液を貧溶媒に滴下等により混合し、式(1)の化合物またはその塩とポリカチオンポリマーとを含んでなる懸濁液を得る。その後、上記懸濁液を洗浄し冷凍した後に乾燥させ、式(1)の化合物またはその塩とポリカチオンポリマーとを含んでなる組成物を得る。得られた組成物は、好ましくは粒子であり、さらに好ましくはナノ粒子等の微粒子である。
上記良溶媒としては、式(1)の化合物またはその塩を溶解できる溶媒であれば特に限定されず、例えば、水、エタノール,イソプロピルアルコールが挙げられ、好ましくは、水、エタノールである。
上記ポリカチオンポリマー溶液に用いる溶媒としては、ポリカチオンポリマーを溶解できる溶媒であれば特に限定されず、例えば、アセトン、ブタノール,酢酸エチル,ジオキサンが挙げられ、好ましくは、アセトン、ブタノールである。上記ポリカチオンポリマー溶液は、界面活性剤を含んでもよい。
したがって、式(1)の化合物またはその塩とポリカチオンポリマーとを溶解させた良溶媒溶液は、良溶媒と共にポリカチオンポリマー溶液における溶媒を含んでよい。
上記貧溶媒としては、式(1)の化合物またはその塩を溶解し難い溶媒であれば特に限定されず、例えば、ヘキサン、ジエチルエーテル,クロロホルム,テトラヒドロキシフランが挙げられ、好ましくは、ヘキサン、ジエチルエーテルである。上記貧溶媒に、界面活性剤、基剤を含んでもよい。
さらに、得られたハイドロゲルをさらに乾燥させて固体状としてもよい。上記乾燥としては、溶媒を十分に乾燥できる手法であれば何ら限定されないが、例えば、噴霧乾燥、凍結乾燥およびそれらの組合せが挙げられる。
化合物1:N-(2-エチルスルホニルアミノ-5-トリフルオロメチル-3-ピリジル)シクロヘキサンカルボキサミド・一ナトリウム塩・一水和物
オイドラギット(登録商標)RSPO:Evonik社製(以下オイドラギットRSという)
オイドラギット(登録商標)RLPO:Evonik社製(オイドラギットRLという)スパン80:Croda international PLC社製
NIKKOL Hexaglyn PR-15:日本サーファクタント工業株式会社製
ココナードMT:花王株式会社製
ポリエチレンオキサイド:重量平均分子量:8,000,000、Sigma Aldrich社製
ε-ポリリジン:重量平均分子量:3,500、奥野製薬工業株式会社製
PLGA:RESOMER RG503、Sigma Aldrich社製
ポリビニルアルコール:重量平均分子量:31,000-50,000、Sigma Aldrich社製
プロタミン硫酸塩:和光純薬社製
ボルテックスミキサー;IKA社製
ホモジナイザー:マイクロテック社製
冷却遠心器:日立工機株式会社製
ディープフリーザー:日本フリーザー株式会社製
凍結乾燥機:FD-1000、東京理化機器株式会社製
振盪器:INCUBATOR M-100、TAITEC株式会社製
超高速液体クロマトグラフィー:Aquity UPLC、Waters株式会社製
微粒子作製装置:スプレードライヤADL311S、ヤマト科学株式会社製
上記超高速液体クロマトグラフィーおよび質量分析は以下の条件で行った。
カラム:Aquity UPLC BEC C18 Column (Waters株式会社製)
カラム温度:40℃
移動相:HPLCグレードメタノール(A),0.1%ギ酸(B)
グラジエント条件:0-0.5分,60% A;0.5-3.5分,
60-80% A
流速:0.25mL/分
注入量:5μL
サンプル温度:15℃
保持時間:2.6分
イオンモード:ES-
m/z:378.1
コーン電圧:60V
キャピラリー電圧:4.00kV
コーンガス:50L/h
ソース温度:120℃
脱溶媒温度:400℃
参考例1-1:化合物1含有組成物(微粒子a)の調製
化合物1(8mg)と精製水(0.8mL)をボルテックスミキサーによって混合し、液体aを得た。PLGA(40mg)、スパン80(40mg)、およびアセトン(1.2mL)をボルテックスミキサーによって混合し、液体bを得た。液体aと液体bをボルテックスミキサーによって混合し液体cを得た。NIKKOL Hexaglyn PR-15(240mg)、ココナードMT(12mL)、およびヘキサン(8mL)をボルテックスミキサーによって混合し、液体dを得た。ポリビニルアルコール(100mg)および精製水(10mL)をマグネチックスターラーによって攪拌し液体eを得た。液体cを液体dに滴下し、ホモジナイザーを用いて、15,000rpmにて5分間攪拌し懸濁液を得た。得られた懸濁液を冷却遠心器によって4℃、20,000rpmにて10分間遠心分離し上清を捨て沈殿を得た。得られた沈殿にヘキサン(10mL)を加えボルテックスミキサーを用いて5分間攪拌し懸濁液とし、冷却遠心器を用いて4℃、20,000rpmにて10分間遠心分離し上清を捨て沈殿を得た。得られた沈殿に液体e(10mL)を加えボルテックスミキサーを用いて5分間攪拌し懸濁液とし、冷却遠心器を用いて4℃、20,000rpmにて10分間遠心分離し上清を捨て沈殿を得た。得られた沈殿に精製水(10mL)を加えボルテックスミキサーを用いて攪拌し懸濁液としディープフリーザーにて-80℃で一晩冷凍した。冷凍後、凍結乾燥機にて二晩凍結乾燥し微粒子aを得た。
参考例1-1で調製した微粒子aの溶出性の評価試験を後述の試験例1と同様に行った。具体的には、微粒子a(10mg)をリン酸緩衝生理食塩水(pH7.4,30mL)に添加し、振盪器を用い、37℃にて24時間、振盪速度60ストローク/分、振盪幅2.0cm/ストロークにて水平振盪し、「溶出性」を評価した。化合物1の濃度の定量はシングル四重極の質量分析器を検出器とする超高速液体クロマトグラフィーを用いて行い、溶出率を算出した。微粒子aの試験結果を、後述の試験例1で得られた化合物1原末の試験結果と併せて下記表1に示す。
試験例1-1:化合物1含有組成物(微粒子A~E)の調製
化合物1(8mg)と精製水(0.8mL)をボルテックスミキサーによって混合し、液体Aを得た。オイドラギットRSとオイドラギットRLの混合物(40mg、オイドラギットRS:RL=100:0、75:25、50:50、25:75および0:100)、スパン80(40mg)、およびアセトン(1.2mL)をボルテックスミキサーによって混合し、液体Bを得た。液体Aと液体Bをボルテックスミキサーによって混合し、液体Cを得た。NIKKOL Hexaglyn PR-15(240mg)、ココナードMT(12mL)、およびヘキサン(8mL)をボルテックスミキサーによって混合し、液体Dを得た。液体Cを液体Dに滴下し、ホモジナイザーを用いて、15,000rpmにて5分間攪拌し懸濁液を得た。得られた懸濁液を冷却遠心器によって4℃、20,000rpmにて10分間遠心分離し上清を捨て沈殿を得た。得られた沈殿にヘキサン(10mL)を加えボルテックスミキサーを用いて5分間攪拌し懸濁液とし、冷却遠心器を用いて4℃、20,000rpmにて10分間遠心分離し上清を捨て沈殿を得た。得られた沈殿に精製水10mLを加えボルテックスミキサーを用いて攪拌し懸濁液としディープフリーザーにて-80℃で冷凍した。冷凍後、凍結乾燥機にて乾燥し微粒子を得た。得られた微粒子のうちオイドラギットRSおよびRLの比(オイドラギットRS:オイドラギットRL)が100:0のものを微粒子A、75:25のものを微粒子B、50:50のものを微粒子C、25:75のものを微粒子D、0:100のものを微粒子Eとした。
試験例1-1で調製した微粒子A、B、C、D、E、および化合物1原末を用いて、各々の溶出性の評価試験を行った。微粒子A、B、C、D、E、および化合物1原末(10mg)を、それぞれリン酸緩衝生理食塩水(pH7.4、30mL)に添加し、振盪器を用い、37℃にて24時間、振盪速度60ストローク/分、振盪幅2.0cm/ストロークにて水平振盪し、「溶出性」を評価した。化合物1の濃度の定量はシングル四重極の質量分析器を検出器とする超高速液体クロマトグラフィーを用いて行い、溶出率を算出した。結果を下記表2および図1に示す。
エマルション溶媒拡散法によって化合物1のような水溶性化合物をポリカチオンポリマー中に封入することで、化合物1の放出速度制御が可能であった。またオイドラギットRSおよびオイドラギットRLの組成を変えることにより放出速度の制御が可能であった。これは、調製した微粒子Fにおいて化合物1がオイドラギットRSおよびオイドラギットRL中に均一分散しており、水が粒子内に侵入した際、化合物1が微粒子表面から徐々に放出されることによると推察する。
微粒子Bの徐放能を評価するため、微粒子Bまたは化合物1原末のラットへの皮下投与後、または化合物1原末のラットへの経口投与後、経時的に化合物1の血中濃度測定を行った。微粒子Bは生理食塩水に懸濁し、化合物1原末は生理食塩水に溶解した後に、それぞれ化合物1の量として5mg/kgをSD系雄性ラットに対して単回投与した。投与後、尾静脈から経時的に採血し、ヘパリン処理をしたマイクロテストチューブに移して、直ちに氷冷した。氷冷後、速やかに血液を4℃、10,000gにて10分間遠心分離した。得られた血漿中の化合物1の濃度はシングル四重極の質量分析器を検出器とする超高速液体クロマトグラフィーによって定量した。
試験例2-1:化合物1含有組成物(微粒子F)の調製
化合物1(600mg)、オイドラギットRS(4050mg)およびオイドラギットRL(1350mg)(オイドラギットRS:RL=75:25)、精製水(12mL)、ならびにエタノール(28mL)を、ボルテックスミキサーを用い混合し、液体Eを得た。得られた液体Eを、噴霧乾燥法による微粒子作製装置を用いて、吐出液滴化し、乾燥させて微粒子Fを得た。なお、条件は下記の通りである。
-微粒子調製条件-
入口温度:130℃
出口温度:77℃以上82℃以下
平均循環風量:0.47m3/min
エアー圧力:0.1MPa
ノズル径:0.4mm
送液速度:3.01g/min
トラップ温度:-2℃
試験例2-1で調製した微粒子Fおよび化合物1原末を用いて、試験例1と同様に、各々の溶出性の評価試験を行った。微粒子F、化合物1原末(10mg)をそれぞれリン酸緩衝生理食塩水(pH7.4、30mL)に添加し、振盪器を用い、37℃にて72時間、振盪速度60ストローク/分、振盪幅2.0cm/ストロークにて水平振盪し、「溶出性」を評価した。結果を下記表4および図3に示す。
噴霧乾燥法によって化合物1のような水溶性化合物をポリカチオンポリマー中に封入することで、化合物1の放出速度制御が可能であった。これは、調製した微粒子Fにおいて化合物1がオイドラギットRSおよびオイドラギットRL中に均一分散しており、水が粒子内に侵入した際、化合物1が微粒子表面から徐々に放出されることによるものと推察する。
微粒子Fの徐放能を評価するため、試験例2-1で調製した微粒子Fまたは化合物1原末をラットに皮下投与後、経時的に化合物1の血中濃度測定を行った。その方法は試験例1-3と同様であった。具体的には、微粒子Fは生理食塩水に懸濁し、化合物1原末は生理食塩水に溶解した後に、それぞれ化合物1の量として5mg/kgをSD系雄性ラットに対して単回皮下投与した。皮下投与後、尾静脈から経時的に採血し、ヘパリン処理をしたマイクロテストチューブに移して、直ちに氷冷した。氷冷後、速やかに血液を4℃、10,000gにて10分間遠心分離した。得られた血漿中の化合物1の濃度はシングル四重極の質量分析器を検出器とする超高速液体クロマトグラフィーによって定量した。結果を図4に示す。下記表5には薬物血中濃度測定の結果から算出した薬物動態学的パラメーターを示す。
化合物1(100mg)、PLGA(500mg)、ならびにアセトンおよびメタノールの混液(アセトン:メタノール(体積比)=2:1,50mL)を、ボルテックスミキサーを用い混合し、液体fを得た。得られた液体fを、噴霧乾燥法による微粒子作製装置を用いて、吐出液滴化し、乾燥させて微粒子bを得た(収率:35%)。なお、条件は下記の通りである。
-微粒子調製条件-
入口温度:60℃
出口温度:50℃以下
平均循環風量:0.51m3/min
エアー圧力:0.3MPa
ノズル径:0.4mm
送液速度:5mL/min
トラップ温度:-2℃
化合物1(100mg)、プロタミン硫酸塩(50mg)、PLGA(500mg)、ならびにアセトンおよびメタノールの混液(アセトン:メタノール(体積比)=2:1,50mL)を、ボルテックスミキサーを用い混合し、液体Fを得た。得られた液体Fを、噴霧乾燥法による微粒子作製装置を用いて、吐出液滴化し、乾燥させて微粒子Gを得た(収率:29%)。なお、条件は下記の通りである。
-微粒子調製条件-
入口温度:60℃
出口温度:50℃以下
平均循環風量:0.51m3/min
エアー圧力:0.3MPa
ノズル径:0.4mm
送液速度:5mL/min
トラップ温度:-2℃
化合物1(100mg)、ε-ポリリジン(60mg)、PLGA(500mg)、ならびにアセトンおよびメタノールの混液(アセトン:メタノール(体積比)=2:1,50mL)を、ボルテックスミキサーを用い混合し、液体Gを得た。得られた液体Gを、噴霧乾燥法による微粒子作製装置を用いて、吐出液滴化し、乾燥させて微粒子Hを得た(収率:32%)。なお、条件は下記の通りである。
-微粒子調製条件-
入口温度:60℃
出口温度:50℃以下
平均循環風量:0.51m3/min
エアー圧力:0.3MPa
ノズル径:0.4mm
送液速度:5mL/min
トラップ温度:-2℃
参考例3-1:化合物1含有組成物(ハイドロゲルa)の調製
化合物1(1.5mg)、ポリエチレンオキサイド(13.5mg)、および精製水(0.9mL)をボルテックスミキサーによって混合し、4℃にて一晩保存しハイドロゲルaを得た。
参考例3-1で調製したハイドロゲルaの徐放能を評価するため、ハイドロゲルaまたは化合物1原末をラットに皮下投与後、経時的に化合物1の血中濃度測定を行った。具体的には、ハイドロゲルaまたは化合物1原末を、化合物1の量として5mg/kgをSD系雄性ラットに対して単回皮下投与した。皮下投与後、経時的に尾静脈から経時的に採血し、ヘパリン処理をしたマイクロテストチューブに移して、直ちに氷冷した。氷冷後、速やかに血液を4℃、10,000gにて10分間遠心分離した。得られた血漿中の化合物1の濃度を、シングル四重極の質量分析器を検出器とする超高速液体クロマトグラフィーによって定量した。結果を図5に示す。下記表6には薬物血中濃度測定の結果から算出した薬物動態学的パラメーターを示す。
試験例5-1:化合物1含有組成物(ハイドロゲルA)の調製
化合物1(1.5mg)、ポリエチレンオキサイド(13.5mg)、ε-ポリリジン(1.5mg)、および精製水(0.9mL)をボルテックスミキサーによって混合し、4℃にて一晩保存しハイドロゲルAを得た。
試験例5-1で調製したハイドロゲルAの徐放能を評価するため、ハイドロゲルAまたは化合物1原末をラットに皮下投与後、経時的に化合物1の血中濃度測定を行った。具体的には、ハイドロゲルAまたは化合物1原末を、化合物1の量として5mg/kgをSD系雄性ラットに対して単回皮下投与した。皮下投与後、経時的に尾静脈から経時的に採血し、ヘパリン処理をしたマイクロテストチューブに移して、直ちに氷冷した。氷冷後、速やかに血液を4℃、10,000gにて10分間遠心分離した。得られた血漿中の化合物1の濃度を、シングル四重極の質量分析器を検出器とする超高速液体クロマトグラフィーによって定量した。結果を図6に示す。下記表7には化合物1の血中濃度測定の結果から算出した薬物動態学的パラメーターを示す。
試験例5のハイドロゲルAのTmax、T1/2は、それぞれ参考例3のハイドロゲルaのTmax、T1/2に比べて延長していた。
Claims (18)
- N-(2-エチルスルホニルアミノ-5-トリフルオロメチル-3-ピリジル)シクロヘキサンカルボキサミドまたはその塩と、
ポリカチオンポリマーと
を含んでなる、局所投与用組成物。 - 前記ポリカチオンポリマーが、陽荷電性窒素原子含有基を有するアクリル酸エステルとメタクリル酸エステルのコポリマー、ポリアミノ酸、ポリアミン、ポリアミドアミン、ポリイミン、キトサン、ポリN,N-ジメチルアミノエチルメタクリル酸、ポリビニルピリジン、ポリイミダゾール、ポリビニルアミン、ポリビニルホルムアミド、プロタミン、ポリチオジエチルアミノメチルエチレン、ポリ-p-アミノスチレン、ポリカチオン炭水化物、ポリカチオンポリメタクリレート、ポリカチオンポリアクリレート、ポリカチオンポリオキセタン、これらの誘導体およびこれらの塩ならびにこれらの組合せからなる群から選択される、請求項1に記載の組成物。
- 陽荷電性窒素原子含有基を有するアクリル酸エステルとメタクリル酸エステルのコポリマーが、アクリル酸エチル・メタアクリル酸メチル・メタアクリル酸トリメチルアンモニウムエチルコポリマーである、請求項2に記載の組成物。
- ポリアミノ酸が、ポリリジン、ポリアルギニン、ポリヒスチジン、およびポリオルニチンからなる群から選択される少なくとも1種である、請求項2に記載の組成物。
- 前記ポリカチオンポリマーが生分解性ポリマーである、請求項1~4のいずれか一項に記載の組成物。
- 前記組成物の形状が粒子である、請求項1~5のいずれか一項に記載の組成物。
- 前記粒子が、溶媒に懸濁した形態である、請求項6に記載の組成物。
- 前記組成物の形状がハイドロゲルである、請求項1~5のいずれか一項に記載の組成物。
- 前記ハイドロゲルが、ポリ(アルキレンオキサイド)、ポリ(ビニルアルコール)、アルギン酸、ヒアルロン酸、コンドロイチン硫酸、ゼラチン、デキストラン、ポリエチレングリコール、メチルセルロース、ヒドロキシメチルセルロース、ヒドロキシエチルセルロース、ポリヒドロキシブテレート、ポリ(n-イソプロピルアクリルアミド)、カラギーナン、ペクチン、硫酸デキストラン、およびそれらの組合せからなる群から選択される親水性ポリマーをさらに含んでなる、請求項8に記載の組成物。
- 前記局所投与が、皮下投与、経直腸投与、腹腔内投与、関節内投与、眼内投与、腫瘍内投与、血管周囲投与、頭蓋内投与、筋肉内投与、眼周囲投与、眼瞼内投与、口腔内投与、鼻腔内投与、膀胱内投与、膣内投与、尿道内投与、直腸内投与、外膜投与、または経鼻投与である、請求項1~9のいずれか一項に記載の組成物。
- 徐放性組成物である、請求項1~10のいずれか一項に記載の組成物。
- 炎症性細胞が関連する疾患、病態、または症状の治療または予防のための、請求項1~11のいずれか一項に記載の組成物。
- 非ヒト動物のための、請求項1~12のいずれか一項に記載の組成物。
- 請求項1~13のいずれか一項に記載の組成物を非ヒト動物に局所投与することを含んでなる、非ヒト動物の炎症性細胞が関連する疾患、病態、または症状の治療または予防方法。
- 請求項1~14のいずれか一項に記載の組成物の製造方法であって、
N-(2-エチルスルホニルアミノ-5-トリフルオロメチル-3-ピリジル)シクロヘキサンカルボキサミドまたはその塩とポリカチオンポリマーとを含む混合物を調製すること
を含んでなる、方法。 - 前記混合物を乾燥させることをさらに含んでなる、請求項15に記載の製造方法。
- 前記乾燥が、噴霧乾燥、凍結乾燥、およびそれらの組合せからなる群から選択される、請求項16に記載の製造方法。
- 前記混合物がN-(2-エチルスルホニルアミノ-5-トリフルオロメチル-3-ピリジル)シクロヘキサンカルボキサミドまたはその塩とポリカチオンポリマーとを溶解させた良溶媒溶液であり、
該良溶媒溶液と貧溶媒とを混合すること
を含んでなる、請求項15に記載の製造方法。
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019550481A JPWO2019088214A1 (ja) | 2017-11-02 | 2018-11-01 | 徐放性医薬組成物 |
US16/760,736 US20200289481A1 (en) | 2017-11-02 | 2018-11-01 | Sustained-release pharmaceutical composition |
KR1020207014153A KR20200083500A (ko) | 2017-11-02 | 2018-11-01 | 서방성 의약 조성물 |
RU2020117897A RU2020117897A (ru) | 2017-11-02 | 2018-11-01 | Фармацевтическая композиция замедленного высвобождения |
CN201880070264.0A CN111315381A (zh) | 2017-11-02 | 2018-11-01 | 缓释性医药组合物 |
BR112020008660-6A BR112020008660A2 (pt) | 2017-11-02 | 2018-11-01 | composição farmacêutica de liberação sustentada |
CA3081177A CA3081177A1 (en) | 2017-11-02 | 2018-11-01 | Sustained-release pharmaceutical composition |
AU2018361503A AU2018361503A1 (en) | 2017-11-02 | 2018-11-01 | Sustained-release medical composition |
MX2020004250A MX2020004250A (es) | 2017-11-02 | 2018-11-01 | Composicion farmaceutica de liberacion sostenida. |
EP18873632.6A EP3705122A4 (en) | 2017-11-02 | 2018-11-01 | DELAYED RELEASE MEDICAL COMPOSITION |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017213144 | 2017-11-02 | ||
JP2017-213144 | 2017-11-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019088214A1 true WO2019088214A1 (ja) | 2019-05-09 |
Family
ID=66331897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/040634 WO2019088214A1 (ja) | 2017-11-02 | 2018-11-01 | 徐放性医薬組成物 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20200289481A1 (ja) |
EP (1) | EP3705122A4 (ja) |
JP (1) | JPWO2019088214A1 (ja) |
KR (1) | KR20200083500A (ja) |
CN (1) | CN111315381A (ja) |
AU (1) | AU2018361503A1 (ja) |
BR (1) | BR112020008660A2 (ja) |
CA (1) | CA3081177A1 (ja) |
MX (1) | MX2020004250A (ja) |
RU (1) | RU2020117897A (ja) |
TW (1) | TW201929851A (ja) |
WO (1) | WO2019088214A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112545977B (zh) * | 2020-12-14 | 2021-08-17 | 黑龙江中医药大学 | 一种治疗盆腔炎的药物组合物及其制备方法 |
CN112353933B (zh) * | 2020-12-14 | 2021-09-24 | 黑龙江中医药大学 | 一种预防和/或治疗子宫肌瘤的药物及其制备方法 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05507494A (ja) * | 1990-06-20 | 1993-10-28 | アドバンスト ポリマー システムズ,インコーポレイティド | 可溶性活性物質の調節された放出のための組成物及び方法 |
JPH06263735A (ja) | 1990-07-10 | 1994-09-20 | Ishihara Sangyo Kaisha Ltd | ジアミノトリフルオロメチルピリジン誘導体、それらの製造方法及びそれらを含有するホスホリパーゼ▲a2▼阻害剤 |
WO1999012571A1 (fr) * | 1997-09-05 | 1999-03-18 | Maruho Kabushikikaisha | Preparations de nanocapsules destinees au traitement de maladies intra-articulaires |
JP2001031591A (ja) * | 1999-06-28 | 2001-02-06 | Adir | 固形の熱成形し得る放出制御医薬組成物 |
WO2001056569A1 (fr) | 2000-02-01 | 2001-08-09 | Ishihara Sangyo Kaisha, Ltd. | Medicaments pour le traitement et la prevention d'affections hepatiques, a base de derives de diaminotrifluoromethylpyridine |
WO2001056568A1 (fr) | 2000-01-31 | 2001-08-09 | Ishihara Sangyo Kaisha, Ltd. | Substances therapeutiques ou preventives pour maladies digestives, contenant des derives de diaminotrifluoromethylpyridine |
WO2001056570A1 (fr) | 2000-02-01 | 2001-08-09 | Ishihara Sangyo Kaisha, Ltd. | Substances therapeutiques ou preventives pour insuffisance pulmonaire, contenant des derives de diaminotrifluoromethylpyridine |
JP2005511523A (ja) * | 2001-10-09 | 2005-04-28 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | ポリカチオンポリマー及び負荷電薬理学的活性化合物を含有する徐放性薬剤送達組成物 |
JP2007246423A (ja) * | 2006-03-15 | 2007-09-27 | Hosokawa Funtai Gijutsu Kenkyusho:Kk | 医薬製剤用または化粧品用材料、並びにそれらを含む医薬製剤または化粧品 |
JP2008280264A (ja) * | 2007-05-09 | 2008-11-20 | Asahi Kasei Pharma Kk | カルシトニン類の徐放性製剤 |
WO2010137484A1 (ja) | 2009-05-28 | 2010-12-02 | 石原産業株式会社 | ジアミノトリフルオロメチルピリジン誘導体を含有する抗ショック剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010056570A (ko) | 1999-12-15 | 2001-07-04 | 이용선 | 휴대용 전자책과 그 전자책의 구동방법 |
KR20010056569A (ko) | 1999-12-15 | 2001-07-04 | 이용선 | 휴대용 전자책과 그 전자책의 구동방법 |
KR20010056568A (ko) | 1999-12-15 | 2001-07-04 | 이용선 | 휴대용 전자책과 그 전자책의 구동방법 |
US20090246529A1 (en) | 2008-03-28 | 2009-10-01 | Conopco, Inc., D/B/A Unilever | Particle with Bipolar Topospecific Characteristics and Process for Preparation Thereof |
-
2018
- 2018-11-01 KR KR1020207014153A patent/KR20200083500A/ko unknown
- 2018-11-01 CA CA3081177A patent/CA3081177A1/en not_active Abandoned
- 2018-11-01 BR BR112020008660-6A patent/BR112020008660A2/pt not_active Application Discontinuation
- 2018-11-01 US US16/760,736 patent/US20200289481A1/en not_active Abandoned
- 2018-11-01 RU RU2020117897A patent/RU2020117897A/ru unknown
- 2018-11-01 WO PCT/JP2018/040634 patent/WO2019088214A1/ja unknown
- 2018-11-01 CN CN201880070264.0A patent/CN111315381A/zh active Pending
- 2018-11-01 EP EP18873632.6A patent/EP3705122A4/en not_active Withdrawn
- 2018-11-01 TW TW107138775A patent/TW201929851A/zh unknown
- 2018-11-01 MX MX2020004250A patent/MX2020004250A/es unknown
- 2018-11-01 JP JP2019550481A patent/JPWO2019088214A1/ja active Pending
- 2018-11-01 AU AU2018361503A patent/AU2018361503A1/en not_active Abandoned
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05507494A (ja) * | 1990-06-20 | 1993-10-28 | アドバンスト ポリマー システムズ,インコーポレイティド | 可溶性活性物質の調節された放出のための組成物及び方法 |
JPH06263735A (ja) | 1990-07-10 | 1994-09-20 | Ishihara Sangyo Kaisha Ltd | ジアミノトリフルオロメチルピリジン誘導体、それらの製造方法及びそれらを含有するホスホリパーゼ▲a2▼阻害剤 |
WO1999012571A1 (fr) * | 1997-09-05 | 1999-03-18 | Maruho Kabushikikaisha | Preparations de nanocapsules destinees au traitement de maladies intra-articulaires |
JP2001031591A (ja) * | 1999-06-28 | 2001-02-06 | Adir | 固形の熱成形し得る放出制御医薬組成物 |
WO2001056568A1 (fr) | 2000-01-31 | 2001-08-09 | Ishihara Sangyo Kaisha, Ltd. | Substances therapeutiques ou preventives pour maladies digestives, contenant des derives de diaminotrifluoromethylpyridine |
WO2001056569A1 (fr) | 2000-02-01 | 2001-08-09 | Ishihara Sangyo Kaisha, Ltd. | Medicaments pour le traitement et la prevention d'affections hepatiques, a base de derives de diaminotrifluoromethylpyridine |
WO2001056570A1 (fr) | 2000-02-01 | 2001-08-09 | Ishihara Sangyo Kaisha, Ltd. | Substances therapeutiques ou preventives pour insuffisance pulmonaire, contenant des derives de diaminotrifluoromethylpyridine |
JP2005511523A (ja) * | 2001-10-09 | 2005-04-28 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | ポリカチオンポリマー及び負荷電薬理学的活性化合物を含有する徐放性薬剤送達組成物 |
JP2007246423A (ja) * | 2006-03-15 | 2007-09-27 | Hosokawa Funtai Gijutsu Kenkyusho:Kk | 医薬製剤用または化粧品用材料、並びにそれらを含む医薬製剤または化粧品 |
JP2008280264A (ja) * | 2007-05-09 | 2008-11-20 | Asahi Kasei Pharma Kk | カルシトニン類の徐放性製剤 |
WO2010137484A1 (ja) | 2009-05-28 | 2010-12-02 | 石原産業株式会社 | ジアミノトリフルオロメチルピリジン誘導体を含有する抗ショック剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3705122A4 |
Also Published As
Publication number | Publication date |
---|---|
EP3705122A4 (en) | 2021-12-22 |
AU2018361503A1 (en) | 2020-05-14 |
US20200289481A1 (en) | 2020-09-17 |
EP3705122A1 (en) | 2020-09-09 |
JPWO2019088214A1 (ja) | 2020-11-19 |
CA3081177A1 (en) | 2019-05-09 |
KR20200083500A (ko) | 2020-07-08 |
CN111315381A (zh) | 2020-06-19 |
BR112020008660A2 (pt) | 2020-10-27 |
RU2020117897A (ru) | 2021-12-02 |
MX2020004250A (es) | 2020-10-22 |
TW201929851A (zh) | 2019-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6282231B2 (ja) | 固化するデポー形成の注入可能な薬物製剤に懸濁される持続放出された生分解性または生体侵食性微小球または微小粒子 | |
JP5780775B2 (ja) | プロスタグランジンi2誘導体を含有するナノ粒子 | |
KR20180006904A (ko) | L-오르니틴 페닐아세테이트의 제형 | |
JP6182313B2 (ja) | 癌治療のためのチオキサントンをベースとしたオートファジー阻害剤療法 | |
WO2019088214A1 (ja) | 徐放性医薬組成物 | |
US20210220428A1 (en) | Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells | |
Tao et al. | Oral delivery of chitosan-coated PLGA nanoemulsion loaded with artesunate alleviates ulcerative colitis in mice | |
Wu et al. | Preparation of betulinic acid galactosylated chitosan nanoparticles and their effect on liver fibrosis | |
EP2515878B1 (en) | Sustained-release formulation | |
US20180243422A1 (en) | Sustained-release formulation | |
CN114569564A (zh) | 戈舍瑞林缓释微球组合物 | |
CN114040751A (zh) | 针对微卫星稳定型结直肠癌通过协同性免疫原性细胞死亡促进抗肿瘤响应的槲皮素和土木香内酯的纳米共递送 | |
CA2812665C (en) | Pharmaceutical composition for treating hcv infections | |
KR20150054543A (ko) | 간 표적화 나노입자, 이의 제조방법 및 이를 포함하는 약학적 조성물 | |
KR102239649B1 (ko) | 염증성 장 질환의 치료를 위한 티아졸로 피리미딘온의 용도 | |
WO2024029331A1 (ja) | 関節疾患の治療及び/又は予防に用いるための医薬組成物 | |
JP2008162904A (ja) | 気管支喘息治療剤 | |
RU2524649C1 (ru) | Способ получения микросфер для приготовления инъецируемой лекарственной формы диклофенака, композиция и лекарственная форма | |
WO2023240035A2 (en) | Conjugate targeting cardiovascular disease | |
Chen et al. | Injectable thermo-sensitive hydrogel enhances anti-tumor potency of engineered Lactococcus lactis by activating dendritic cells and effective memory T cells | |
CN113905764A (zh) | 用于治疗癌症的前体半胱天冬酶-3活化作用和免疫疗法 | |
WO2024068672A1 (en) | Structured lipid compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18873632 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3081177 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2019550481 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018361503 Country of ref document: AU Date of ref document: 20181101 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20207014153 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018873632 Country of ref document: EP Effective date: 20200602 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112020008660 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112020008660 Country of ref document: BR Kind code of ref document: A2 Effective date: 20200430 |